|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Rivaroxaban( BAY 59-7939) an oral direct factor Xa inhibitor has nolinically relevant interaction with naproxen 显示文摘 | Kubitza D Michaell B Wolfgang M | 2007 | Br J Clin Pharm2007，4，63： | 1 |
| 2 | Safety,pharmacodynamics,and pharmacokinetics of single doses of BAY 59-7939,an oral,direct factor Xa inhibitor显示文摘 | Kubitza D Becka M Voith B | | 0，，： | 1 |
| 3 | Safety, pharmaco- dynamics, and pharmacokinetics of single doses of BAY 59-7939 an oral, direct factor X a inhibitor 显示文摘 | Kubitza D Becka M Voith B | 2005 | Clin Pharmacol Ther2005，78，4： | 1 |
| 4 | Safety, tol- erability, pharmacodynamics, and pharmacokinetics of rivaroxaban an oral, direct factor Xa inhibitor are not af- fected by as- pirin显示文摘 | Kubitza D Michaell B Wolfgang M etal | 2006 | J Clin Pharmacol2006，46，10： | 1 |
| 5 | Safety,pharmacodynamics,and pharmacokinetics of single doses of BAY 59-7939,an oral,direct factor Xa inhibitor显示文摘 | KUBITZA D BECKA M VOITH B | 2005 | Clin Pharmacol Ther2005，78，4： | 1 |
| 6 | Safety, phannacodynam- ies, and pharmacokineties of single doses of BAY 59-7939, an oral, direct factor Xa inhibitor 显示文摘 | Kubitza D Beeka M Voith B | 2005 | Clin Pharmacol Therapeut2005，78，4： | 1 |
| 7 | Rivaroxaban (BAY 59-7939) an oral, direct factor Xa inhibitor has no clinically relevant interaction with naproxen 显示文摘 | KUBITZA D MICHAELL B WOLFGANG M | 2007 | Br J Clin Pharm2007，4，63： | 1 |
| 8 | Safety, pharmacodynam- ics, and pharmacokinetics of single doses of BAY59 - 7939, an oral, direct factor Xa inhibitor 显示文摘 | Kubitza D Becka M Voith B | 2005 | Clin Pharmacol Ther2005，78，4： | 1 |
| 9 | Safety, tolerability, pharmacodynamics, and pharmacokinetics of rivaroxaban-an oral, direct factor Xa inhibitor-are not affected by aspirin 显示文摘 | KUBITZA D MICHAELL B WOLFGANG M | 2006 | J Clin Pharmacol2006，46，10： | 1 |
| 10 | Safety, pharmacodynamics, and pharmacokinetics of single doses of BAY 59-7939, an oral, direct factor Ⅹa inhibitor显示文摘 | KUBITZA D BECKA M VOITH B | 2005 | Clin Pharmacol Ther2005，78，4： | 1 |
| 11 | Safety, pharmacodynamics, and pharmacokinetics of single doses of BAY 59-7939, an oral, direct factor Xa inhibitor显示文摘 | Kubitza D Becka M Voith B | 2005 | Clin Pharmacol Ther2005，78，4： | 1 |
| 12 | Safety,pharmacodynamics,and pharmacokinetics of single doses of BAY 59-7939,an oral,direct factor Ⅹa inhibitor显示文摘 | Kubitza D Becka M Voith B | 2005 | Clin Pharmacol Ther2005，78，4： | 1 |
| 13 | Safety, pharmacody- namics, and pharmacokinetics of single doses of BAY 59-7939,an oral, direct factor X a inhibitor显示文摘 | Kubitza D Becka M Voith B | 2005 | Clin Pharmacol Ther2005，78，： | 1 |
| 14 | R ivaroxaban (BAY 59-7939) an oral, direct factor Xa inhibitor has no clinically relevant interaction with nap roxen 显示文摘 | Kubitza D Michaell B Wolfgang M | 2007 | B r J ClinPharm2007，4，63： | 1 |
| 15 | Safety, pharmaco- dynamics, and pharmacokinetics of single doses of BAY 59- 7939, an oral, direct factor Xa inhibitor 显示文摘 | KUBITZA D BECKA M VOITH B | 2005 | Clin Pharmacol Ther2005，78，4： | 1 |
| 16 | Safety, tolerability, pharmacedynamics, and pharmacokinetics of rivaroxaban2an oral, direct factor Xa inhibitor2are not affected by asp irin 显示文摘 | Kubitza D Michaell B Wolfgang M | 2006 | J Clin Pharmacol2006，46，10： | 1 |
| 17 | Safety, pharmacodynamics, and pharmacokinetics of single doses of BAY 59-7939, an oral, direct factor Xa inhibitor显示文摘 | Kubitza B Becka M Voith B | 2005 | Clin Pharmacol Ther2005，78，4： | 1 |
| 18 | Safe~, pharmacodynamics, and pharmacokinetics of BAY 59-7939-an oral, direct Factor Xa inhibitor- after multiple dosing in healthy male subjects显示文摘 | Kubitza B Becka M Wensing G | 2005 | EurJ Clin Pharmacol2005，61，12： | 1 |
| 19 | Safety,pharmacodynamics,and pharmacokinetics of single doses of BAY 59-7939,an oral,direct factor Xa inhibitor显示文摘 | Kubitza D Becka M Voith B | 2005 | C1in Pharmacol Ther2005，78，4： | 1 |
| 20 | Safety, pharmacodynamics, and pharmacokinetics of single doses of BAY 59 -7939, an oral, direct factor Xa inhibitor 显示文摘 | Kubitza D Becka M Yoith B | 2005 | Clin Phamlacol Ther2005，78，4： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员